Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Receivables - Accured (2019 - 2025)

Fate Therapeutics (FATE) has disclosed Receivables - Accured for 7 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Accured fell 66.67% year-over-year to $700000.0, compared with a TTM value of $700000.0 through Dec 2025, down 66.67%, and an annual FY2025 reading of $700000.0, down 66.67% over the prior year.
  • Receivables - Accured was $700000.0 for Q4 2025 at Fate Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $2.1 million in Q2 2021 and bottomed at $1000.0 in Q2 2022.
  • Average Receivables - Accured over 5 years is $1.3 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Receivables - Accured crashed 99.95% in 2022, then soared 154445.45% in 2024.
  • Year by year, Receivables - Accured stood at $1.1 million in 2021, then dropped by 27.27% to $800000.0 in 2022, then grew by 12.5% to $900000.0 in 2023, then surged by 133.33% to $2.1 million in 2024, then crashed by 66.67% to $700000.0 in 2025.
  • Business Quant data shows Receivables - Accured for FATE at $700000.0 in Q4 2025, $1.4 million in Q3 2025, and $2.0 million in Q2 2025.